Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Secondary Polycythemia Clinical Presentation

  • Author: Srikanth Nagalla, MBBS, MS, FACP; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
 
Updated: Apr 14, 2016
 

History

Patients with a high red blood cell mass usually have plethora or a ruddy complexion. However, if the polycythemia is secondary to hypoxia, as in venous-to-arterial shunts or compromised lung and oxygenation, patients can also appear cyanotic.

Increased red blood cell mass increases blood viscosity and decreases tissue perfusion. With impaired circulation to the central nervous system, patients may present with headaches, lethargy, and confusion or more serious presentations, such as stroke and obtundation. In addition, polycythemia potentially predisposes patients to thrombosis.

Congenital heart diseases manifest at birth or in early childhood. In some cases, a family history of congenital heart disease may be present.

Patients with familial hemoglobinopathies that result in increased oxygen affinity usually have a family history of similar problems in several family members, although significant numbers of patients with congenital polycythemia have no family history of similar disorders.[4]

Chronic pruritus in the absence of a rash is more indicative of a primary myeloproliferative disorder rather than secondary polycythemia.

Next

Physical

Plethora manifests as increased redness of the skin and mucosal membranes. This finding is easier to detect on the palms or soles, where the skin is light in dark-skinned individuals. Some patients may have acrocyanosis caused by sluggish blood flow through small blood vessels.

The presence of splenomegaly supports a diagnosis of polycythemia vera rather than secondary polycythemia. Cardiac murmurs and clubbing of the fingers may suggest a congenital heart disease.

Previous
Next

Causes

Secondary polycythemia is defined as an absolute increase in red blood cell mass that is caused by enhanced stimulation of red blood cell production. In contrast, polycythemia vera is characterized by bone marrow with an inherent increased proliferative activity.[1, 3, 5, 6, 7, 8, 9, 10] Approximately two thirds of patients with polycythemia vera have elevated white blood cell (granulocyte, not lymphocyte) counts and platelet counts.[11] No other causes of polycythemia/erythrocytosis are associated with elevated granulocyte or platelet counts.

Enhanced erythroid stimulation can be a physiologic response to generalized or localized tissue hypoxia,[12] as in the following settings:

  • Decreased ambient oxygen concentration, as occurs in people living at high altitudes, can result in compensatory erythrocytosis as a physiologic response to tissue hypoxia. [13]
  • Chronic obstructive pulmonary disease is commonly due to a large amount of ventilation in poor gas exchange units (high ventilation-to-perfusion ratios). [14]
  • Alveolar hypoventilation can result from periodic breathing and oxygen desaturation (sleep apnea) or morbid obesity (Pickwickian syndrome).
  • Cardiovascular diseases associated with a right-to-left shunt (arteriovenous malformations) can result in venous blood mixing in the arterial system and delivering low oxygen levels to tissues.
  • Hemoglobin abnormalities associated with high oxygen affinity and congenital defects can lead to oxidized or methemoglobin. These conditions are usually familial.
  • Exposure to carbon monoxide by smoking or working in automobile tunnels results in an acquired condition. [15, 16] Carboxyhemoglobin has a strong affinity for oxygen.

Impaired perfusion of the kidneys, which may lead to stimulation of erythropoietin [EPO] production, is usually due to local renal hypoxia in the absence of systemic hypoxia. Conditions include the following:

  • Arteriosclerotic narrowing of the renal arteries or graft rejection of a transplanted kidney can lead to impaired kidney perfusion.
  • Aneurysms affecting the aorta and renal vessels can lead to kidney infarction and hypoxia.
  • Focal glomerulonephritis has been associated with secondary polycythemia, although the mechanism for stimulation of EPO secretion in this condition remains unknown.
  • Polycythemia occurring after renal transplantation is not a rare event. The mechanisms involved have not been clearly demonstrated.

Inappropriate stimulation of EPO production

Inappropriate stimulation of EPO production may occur in the following settings:

  • Benign renal lesions, such as hydronephrosis and cysts, can stimulate EPO production, possibly due to compromised renal blood flow by compressive or vasoconstrictive mechanisms.
  • Malignant and benign tumors that secrete EPO have been observed in patients with renal carcinomas, cerebellar hemangioblastomas, adrenal carcinomas, adrenal adenomas, hepatomas, and uterine leiomyomas.
  • Blood doping is an illegal practice. Competitive athletes have been known to attempt to maintain an advantage over their opponent by autologous blood transfusions or self-administration of recombinant EPO. Several deaths have been attributed to excessive blood doping.
  • Illicit use of androgenic steroids to build muscles and strength can also increase red blood cell mass by stimulating endogenous serum EPO levels.

Congenital causes

Hemoglobin mutants associated with tight binding to oxygen and a failure to deliver oxygen in the venous blood can cause high EPO levels. The high level of EPO is compensatory to elevate hemoglobin levels to deliver an optimal amount of oxygen to the tissues. Hypoxia-inducible factor 1-alpha (HIF1-alpha) binds to the hypoxia-responsive element, which is downstream of the gene for EPO. The activity of HIF1-alpha is increased by a lowered oxygen tension.

A von Hippel-Lindau gene mutation results in polycythemia by altering the von Hippel-Lindau protein, which plays an important role in sensing hypoxia and binds to hydroxylated HIF1-alpha to serve as a recognition site of an E3-ubiquitin ligase complex. In this condition, and in hypoxia, the undegraded HIF1-alpha forms a heterodimer with HIF-beta and leads to increased transcriptions of the gene for EPO.

Chuvash polycythemia is caused by an autosomal recessive gene mutation on the von Hippel-Lindau gene, which results in the upregulation of the HIF1-alpha target gene and causes elevations in EPO levels.[17]

Low EPO-dependent polycythemias

These are called primary familial and congenital polycythemias.[18] The EPO receptor mutation results in a gain of function, and patients have normal-to-high hematocrit values and low EPO levels.[19] These conditions can be acquired from (1) insulinlike growth factor-1 (IGF-1), a well-known stimulator of erythropoiesis, and (2) cobalt toxicity, which can induce erythropoiesis.

Testosterone-associated polycythemia

The administration of androgen esters to hypogonadal men can lead to polycythemia. However, the incidence of testosterone-associated polycythemia may be lower in men receiving pharmacokinetically steady-state delivery of testosterone formulations, as occurs following the subcutaneous implantation of testosterone pellets, than it is in men receiving intramuscular injections of shorter-acting androgen esters.

Ip and colleagues found that in men receiving long-acting depot testosterone treatment, the development of polycythemia (hematocrit >50%) was predicted by higher trough serum testosterone concentrations but not by the duration of treatment.[20]

Previous
 
 
Contributor Information and Disclosures
Author

Srikanth Nagalla, MBBS, MS, FACP Director, Clinical Hematology, Cardeza Foundation for Hematologic Research; Assistant Professor of Medicine, Division of Hematology, Associate Program Director, Hematology/Medical Oncology Fellowship, Assistant Program Director, Internal Medicine Residency, Jefferson Medical College of Thomas Jefferson University

Srikanth Nagalla, MBBS, MS, FACP is a member of the following medical societies: American Society of Hematology, Association of Specialty Professors

Disclosure: Nothing to disclose.

Coauthor(s)

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Koyamangalath Krishnan, MD, FRCP, FACP Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

Karen Seiter, MD Professor, Department of Internal Medicine, Division of Oncology/Hematology, New York Medical College

Karen Seiter, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology

Disclosure: Received honoraria from Novartis for speaking and teaching; Received consulting fee from Novartis for speaking and teaching; Received honoraria from Celgene for speaking and teaching.

References
  1. Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004 May 1. 69(9):2139-44. [Medline]. [Full Text].

  2. Passamonti F. How to manage polycythemia vera. Leukemia. 2011 Dec 9. [Medline].

  3. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008 Dec. 30(6):447-59. [Medline].

  4. Esparcieux A, Francina A, Vital-Durand D. [Abnormal haemoglobins with high oxygen affinity in the differential diagnostics of polycythemia]. Rev Med Interne. 2011 Oct. 32(10):e105-7. [Medline].

  5. Balcerzak SP, Bromberg PA. Secondary polycythemia. Semin Hematol. 1975 Oct. 12(4):353-82. [Medline].

  6. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol. 1999 Mar. 6(2):100-9. [Medline].

  7. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009 May. 23(5):834-44. [Medline].

  8. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008 Dec. 30(6):447-59. [Medline].

  9. Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol. 2009 May. 7(5):334-42. [Medline].

  10. Carillo S, Henry L, Lippert E, Girodon F, Guiraud I, Richard C, et al. Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia. J Mol Diagn. 2011 May. 13(3):263-70. [Medline]. [Full Text].

  11. Squizzato A, Romualdi E, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2008 Apr 16. CD006503. [Medline].

  12. Lee FS. Genetic causes of erythrocytosis and the oxygen-sensing pathway. Blood Rev. 2008 Nov. 22(6):321-32. [Medline].

  13. Gonzales GF, Gasco M, Tapia V, Gonzales-Castañeda C. High serum testosterone levels are associated with excessive erythrocytosis of chronic mountain sickness in men. Am J Physiol Endocrinol Metab. 2009 Jun. 296(6):E1319-25. [Medline]. [Full Text].

  14. Patakas DA, Christaki PI, Louridas GE, Sproule BJ. Control of breathing in patients with chronic obstructive lung diseases and secondary polycythemia after venesection. Respiration. 1986. 49(4):257-62. [Medline].

  15. Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am Rev Respir Dis. 1982 May. 125(5):507-10. [Medline].

  16. Schwarcz TH, Hogan LA, Endean ED, et al. Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia. J Vasc Surg. 1993 Mar. 17(3):518-22; discussion 522-3. [Medline].

  17. Percy MJ, Beard ME, Carter C, Thein SL. Erythrocytosis and the Chuvash von Hippel-Lindau mutation. Br J Haematol. 2003 Oct. 123(2):371-2. [Medline].

  18. Van Maerken T, Hunninck K, Callewaert L, et al. Familial and congenital polycythemias: a diagnostic approach. J Pediatr Hematol Oncol. 2004 Jul. 26(7):407-16. [Medline].

  19. Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997 Sep 1. 90(5):2057-61. [Medline]. [Full Text].

  20. Ip F, di Pierro I, Brown R, et al. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol. 2009 Nov 10. [Medline].

  21. Remacha AF, Montserrat I, Santamaria A, et al. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. Haematologica. 1997 Jul-Aug. 82(4):406-10. [Medline]. [Full Text].

  22. Sondel PM, Tripp ME, Ganick DJ, Levy JM, Shahidi NT. Phlebotomy with iron therapy to correct the microcytic polycythemia of chronic hypoxia. Pediatrics. 1981 May. 67(5):667-70. [Medline].

  23. Kershenovich S, Modiano M, Ewy GA. Markedly decreased coronary blood flow in secondary polycythemia. Am Heart J. 1992 Feb. 123(2):521-3. [Medline].

  24. Lubarsky DA, Gallagher CJ, Berend JL. Secondary polycythemia does not increase the risk of perioperative hemorrhagic or thrombotic complications. J Clin Anesth. 1991 Mar-Apr. 3(2):99-103. [Medline].

  25. Menon D, York EL, Bornstein RA, Jones RL, Sproule BJ. Optimal hematocrit and blood viscosity in secondary polycythemia as determined from cerebral blood flow. Clin Invest Med. 1981. 4(2):117-21. [Medline].

  26. Rapado I, Albizua E, Ayala R, Hernández JA, Garcia-Alonso L, Grande S, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008 Sep. 87(9):741-9. [Medline].

  27. York EL, Jones RL, Menon D, Sproule BJ. Effects of secondary polycythemia on cerebral blood flow in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980 May. 121(5):813-8. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.